In our study, the higher pretreatment GAS1 levels in the partially responding laBCCs may suggest that these tumours were more aggressive and therefore able to spread even with these GAS1 levels, making them relatively resistant to the systemic treatment. The gene discussed is GAS1; the disease is neoplasm.